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ABSTRACT
Aims/Introduction: Advanced glycation end-products (AGEs), which are a major cause
of diabetic vascular complications, accumulate in various tissues under chronic hyper-
glycemic conditions, as well as with aging in patients with diabetes. The loss of muscle
mass and strength, so-called sarcopenia and dynapenia, has recently been recognized as
a diabetic complication. However, the influence of accumulated AGEs on muscle mass
and strength remains unclear. The present study aimed to evaluate the association of sar-
copenia and dynapenia with accumulated AGEs in patients with type 2 diabetes.
Materials and Methods: We recruited 166 patients with type 2 diabetes aged
≥30 years (mean age 63.2 – 12.3 years; body mass index 26.3 – 4.9 kg/m2; glycated
hemoglobin 7.1 – 1.1%). Skin autofluorescence as a marker of AGEs, limb skeletal muscle
mass index, grip strength, knee extension strength and gait speed were assessed.
Results: Sarcopenia and dynapenia were observed in 7.2 and 13.9% of participants,
respectively. Skin autofluorescence was significantly higher in patients with sarcopenia and
dynapenia. Skin autofluorescence was the independent determinant for skeletal muscle
mass index, grip strength, knee extension strength, sarcopenia and dynapenia.
Conclusions: Accumulated AGEs could contribute to reduced muscle mass and
strength, leading to sarcopenia and dynapenia in patients with type 2 diabetes.
INTRODUCTION
The increase of elderly patients with type 2 diabetes is a major
problem all over the world, especially in Japan. Sarcopenia, an
age-related decrease in the strength of skeletal muscle accompa-
nied with the loss of muscular mass, is known to impair physi-
cal ability1,2 and increase the risk of incidental falls3. Patients
with type 2 diabetes are reportedly candidates for sarcopenia4,5.
These patients have low muscle mass and strength in the lower
extremities despite having identical grip strength to healthy
individuals, which might cause mobility limitations6. In con-
trast, an age-related decline in muscle strength before the
reduction of muscle mass is proposed to be “dynapenia”7,8.
However, the clinical impact of dynapenia on physical activity
and the risk of incidental falls in patients with type 2 diabetes
has not been determined.
Advanced glycation end-products (AGEs), produced by non-
enzymatic binding of glucose and proteins, accumulate in
various tissues with aging9–12. Chronic hyperglycemia also
accelerates AGEs accumulation, which causes diabetic vascular
complications, such as macro- and micro-angiopathy, through
oxidative stress and chronic inﬂammation9. A longer duration
of diabetes or sustained hyperglycemia is suggested to be rele-
vant to muscle weakness in patients with diabetes13. However,
the relationship among AGEs accumulation in patients with
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type 2 diabetes and reduced muscle mass and strength, and
physical performance is unclear. In addition, the association
between AGEs accumulation and dynapenia in patients with
type 2 diabetes has not been determined. Therefore, the aim of
the present cross-sectional study was to investigate the clinical
impact of sarcopenia and dynapenia, and clarify the inﬂuence
of AGEs accumulation on muscle mass and strength in patients
with type 2 diabetes.
MATERIAL AND METHODS
Study design and participants
The present study was approved by the ethics committee of
Tokushima University Hospital (approval #2281). The inclusion
criteria were outpatients with type 2 diabetes aged ≥30 years at
Tokushima University Hospital. Written informed consent was
obtained from all participants. Patients who were taking ster-
oids, and those with severe peripheral neuropathy, end-stage
renal failure, history of stroke, myopathy and motor func-
tional disorders were excluded. A cross-sectional analysis was
carried out of each set of data obtained from July until Decem-
ber 2016.
Assessment of body composition and muscle strength
The body mass index (BMI) was determined by the formula of
bodyweight (kg) divided by height squared (m2). Percentage
body fat (%body fat) and skeletal muscle mass were measured
as previously reported using the bioelectrical impedance analy-
sis-based measurements14, which was shown to have a strong
positive correlation with dual-energy X-ray absorptiometry in
elderly individuals3,15. Skeletal muscle mass index (SMI) was
calculated by dividing the upper- and lower-limb skeletal mus-
cle mass by height squared1,2. Visceral fat area was measured
with a medical visceral fat measuring device using multifre-
quency bioelectrical impedance analysis (HDS-2000 DUALS-
CAN; OMRON, Kyoto, Japan).
Grip strength, knee extension strength and gait speed were
determined to evaluate muscle strength and physical perfor-
mance. Upper extremity muscle strength was measured with
each hand using maximum isometric grip strength (GRIP-D
TKK5401; Takei, Niigata, Japan) in a standing position1–3. The
highest grip strength value was used as the muscle strength in
the present study. A handheld dynamometer (lTas F-1;
ANIMA, Tokyo, Japan) was utilized to evaluate maximum iso-
metric knee extension strength, which represents lower extrem-
ity muscle strength. The participants sat on a bench and the
force sensor was ﬁxed ﬁrmly by a belt on the distal end of the
tibia to a rigid bar. We deﬁned the maximal isometric knee
extension strength as the highest value of three trials16. We
multiplied the maximal isometric knee extension strength and
the lever arm strength to calculate knee extension torque (Nm).
The knee extension torque divided by bodyweight (Nm/kg)
was calculated to estimate the knee extension strength. Mea-
sured body height was used to estimate lever arm strength17,18.
The total 5-m walk time was recorded as gait speed1–3.
Deﬁnition of sarcopenia and dynapenia
We used the deﬁnition of sarcopenia proposed by the Asian
Working Group for Sarcopenia2, which involves low handgrip
strength, slow gait speed and low SMI. The cut-off values of
low muscle mass, strength and physical performance according
to the deﬁnition of sarcopenia and dynapenia are shown in
Appendix S1. Dynapenia was deﬁned according to the pro-
posed criteria by Clark and Manini as low handgrip strength,
low knee extension strength and a normal SMI7,8,18. Patients
who were not diagnosed with sarcopenia or dynapenia were
deﬁned as the control group.
Skin autoﬂuorescence measurement
Skin autoﬂuorescence (AF) has been proposed as a marker of
AGEs accumulation in the skin19. Skin AF was strongly corre-
lated with the speciﬁc AGEs content in skin biopsy samples as
reported previously20,21. Skin AF was measured by an
AGE ReaderTM (DiagnOptics Technologies BV, Groningen, the
Netherlands), which estimates skin accumulation of AGEs
according to the ﬂuorescence properties of AGEs. The measure-
ment protocol was reported in detail previously19–21. Skin AF
was measured on the ventral side of the forearm three times in
series, and the averaged value was utilized in the present study.
Repeated skin AF measurements within a day showed an over-
all Altman error rate of 5.03%20.
Clinical laboratory data
Glycated hemoglobin (HbA1c), serum high-density lipoprotein
cholesterol, serum triglyceride and serum creatinine were exam-
ined in the hospital using standard laboratory methods. The
duration of diabetes, history of hypertension and dyslipidemia,
and use of antidiabetic medications were collected from the
medical records of each individual participant. The estimated
glomerular ﬁltration rate (eGFR) was calculated using the
following equation (eGFR = 194 9 serum creatinine [mg/
dL] - 1.094 9 age - 0.287 [90.739 for females]), and
eGFR <60 mL/min/1.73 m3 was deﬁned as chronic kidney dis-
ease according to the criteria of Japanese Society of Nephrol-
ogy22. Serum pentosidine, one of AGEs in the circulation10, was
measured using a competitive enzyme-linked immunosorbent
assay kit. Blood pressure was measured with patients in the
supine position.
Diabetic neuropathy was diagnosed in patients who fulﬁlled
at least two of the following criteria: complaint of bilateral
sensory symptoms in the toes and soles of the feet (speciﬁ-
cally, at least two of the following: numbness, pain and dyses-
thesia), a bilaterally diminished or absent Achilles tendon
reﬂex, and a bilaterally decreased vibratory sensation in the
inner malleolus23.
Assessment of physical activity and history of falls
The diagnostic survey method with a short version of the Inter-
national Physical Activity Questionnaire24,25 was used to esti-
mate physical activity in each patient. The time spent within a
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week (7 days) on various activities which, depending on their
intensity, were ascribed a speciﬁed metabolic equivalent of
1 kcal/kg/h (MET). The International Physical Activity Ques-
tionnaire questionnaires collected MET data for each partici-
pant. The short version of the International Physical Activity
Questionnaire details moderate (four MET) and intensive (eight
MET) physical activity, as well as walking (3.3 MET). The data
collected from the questionnaires were used to calculate the
weekly energy consumption (EC) expressed as kilocalories per
week25. An interview was carried out about the history of falls
within the past year for each participant. A history of falls was
deﬁned as one or more falls. A “fall event” was identiﬁed for
each participant who suddenly lost his/her balance and
collapsed3,26.
Statistical analysis
SPSS Statistics 22 (IBM Japan, Tokyo, Japan) was used for the
statistical processing. All data are presented as mean – standard
deviation. Intergroup comparisons (control of non-sarcopenia
and dynapenia, sarcopenia, dynapenia) were assessed using an
unpaired one-way analysis of variance (continuous variables) or
v2-test (categorical variables). Uni- and multivariate logistic
regression analyses were used to calculate the cross-sectional
association of a low SMI, low grip strength, slow gait speed,
low knee extension strength, sarcopenia and dynapenia (input
of covariates: age, female sex, %body fat, HbA1c, skin AF,
serum pentosidine, eGFR, diabetic neuropathy and EC). Using
the logistic regression models, the odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were calculated. Using a stepwise
procedure, covariates in the multivariate logistic regression anal-
yses were selected. The correlation analysis between skin AF/
pentosidine and other clinical parameters used Pearson’s corre-
lation coefﬁcient and multiple regression analyses. Statistical sig-
niﬁcance was deﬁned as a P-value <0.05.
RESULTS
Clinical characteristics of sarcopenia and dynapenia
The total of 166 Japanese participants with type 2 diabetes (99
men, 67 women) aged ≥30 years was enrolled in the present
study. The prevalence of sarcopenia, dynapenia and those com-
ponents are shown in Figure 1. Of all participants with type 2
diabetes, 7.2% were diagnosed with sarcopenia and 13.9% with
dynapenia. Patients with type 2 diabetes aged ≥65 years had a
signiﬁcantly higher rate of sarcopenia and dynapenia than those
aged <65 years (sarcopenia: P = 0.033, dynapenia: P < 0.001).
The prevalence of low SMI, low grip strength, slow gait speed
and low knee extension strength were 11.5, 22.3, 6.6 and
59.0%, respectively. The patients aged ≥65 years had a signiﬁ-
cantly higher rate of low SMI, low grip strength and low gait
speed values than those aged <65 years (low SMI: P = 0.014,
low grip strength: P < 0.001, slow gait speed: P = 0.001). In
contrast, there was no signiﬁcant difference in the prevalence of
low knee extension strength between patients aged ≥65 and
<65 years.
The clinical characteristics of the study patients with sar-
copenia and dynapenia are shown in Table 1, and Appen-
dices S2 and S3. Sarcopenic patients were older with longer
duration of diabetes, and had a higher rate of incidental
falls, skin AF and serum pentosidine, and lower BMI and
%body fat than those of control patients. In contrast, dyna-
penic patients with type 2 diabetes were also older with
longer duration of diabetes, and had higher percentage
incidence of falls and skin AF, but had higher BMI and %
body fat than those of control patients (Table 1). Dynape-
nic patients had higher BMI, %body fat and visceral fat
area, and had a lower skin AF than those of sarcopenic
patients (Table 1).
ORs for low muscle mass, strength and physical performance
The ORs of clinical parameters for low muscle mass and
strength, and physical performance in patients with type 2 dia-
betes are shown in Table 2. Skin AF and serum pentosidine
were inversely associated with SMI in the univariate model.
After the adjustment for all covariates on stepwise regression,
skin AF and serum pentosidine remained to be inversely associ-
ated with SMI (skin AF: OR 6.38, 95%CI 1.93–21.08; serum
pentosidine: OR 1.02, 95%CI 1.00–1.03).
Skin AF and serum pentosidine were also inversely asso-
ciated with grip strength and knee extension strength,
respectively, in the univariate model. Skin AF remained to
be inversely associated with grip strength and knee exten-
sion strength (grip strength: OR 3.55, 95% CI 1.57–8.00;
knee extension strength: OR 3.68, 95% CI 1.87–7.23) after
adjustment for all covariates by stepwise regression. The
results of the present study showed that skin AF was an
independent determinant of low SMI, low grip strength
and knee extension strength.
ORs for the risk of sarcopenia and dynapenia
The ORs of the risk for sarcopenia and dynapenia in type 2
diabetes patients are shown in Table 3. Age, skin AF, serum
pentosidine, and a decrease in eGFR and %body fat were sig-
niﬁcantly associated with the prevalence of sarcopenia in a uni-
variate model (Table 3). The association between skin AF and
the prevalence of sarcopenia remained signiﬁcant (skin AF: OR
7.73, 95% CI 2.13–28.02) after the adjustment for all covariates
by stepwise regression.
Age, %body fat and skin AF were signiﬁcantly associated
with the prevalence of dynapenia in a univariate analysis. Per-
centage body fat and skin AF are signiﬁcantly associated with
the prevalence of dynapenia (%body fat: OR 1.11, 95% CI
1.03–1.19; skin AF: OR 3.03, 95% CI 1.07–8.54) after the
adjustment for all covariates by stepwise regression. Elevation
of skin AF was the independent risk factor for both sarcopenia
and dynapenia.
In contrast, the use of antidiabetic agents was not signiﬁ-
cantly associated with sarcopenia nor dynapenia on the univari-
ate and multivariate analyses (Appendix S3).
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Correlation analysis between skin AF/pentosidine and other
clinical parameters
The correlation analysis between skin AF/pentosidine and other
clinical parameters is shown in Appendix S4. Skin AF was sig-
niﬁcantly correlated with circulating serum pentosidine, and
these markers of AGEs were correlated with age, duration of
diabetes and decrease in eGFR. In addition, skin AF was inver-
sely correlated with BMI and EC. Multiple regression analyses
showed that the age, duration of diabetes and EC were inde-
pendent determinants of skin AF (age: b = 0.189, P = 0.025,
duration of diabetes: b = 0.165, P = 0.049, EC: b = -0.208,
P = 0.010), and the duration of diabetes and eGFR were signiﬁ-
cantly associated with serum pentosidine level (duration of dia-
betes: b = 0.195, P = 0.018, eGFR: b = -0.279, P = 0.001).
DISCUSSION
Here, we showed for the ﬁrst time that dynapenia is observed
approximately twofold more frequently than sarcopenia, and
these complications are associated with a comparable incidence
of incidental falls in patients with type 2 diabetes. The typical
clinical characteristics of dynapenia are high %body fat, as well
as aging. In addition, accumulated AGEs were signiﬁcantly
associated with low muscle strength, as well as low muscle
mass, and related to the prevalence of sarcopenia and dynape-
nia in patients with type 2 diabetes.
The previous studies showed that the prevalence of sarcope-
nia was 4.1–11.5% in the general elderly population27 and
14.8% in type 2 diabetespatients28 according to the Asian
Working Group for Sarcopenia criteria. In contrast, the preva-
lence rate of dynapenia, deﬁned by low handgrip strength and
normal SMI, was 35.0% in men (mean age 83.8 – 6.8 years)
and 27.1% in women (mean age 82.5 – 6.4 years) of general
elderly Japanese aged ≥65 years, and those were twofold higher
than those of sarcopenia (men 25.0%, women 22.7%)29. In the
present study, we conﬁrmed an equivalent prevalence rate of
sarcopenia in patients with type 2 diabetes, and that the
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Figure 1 | Prevalence of sarcopenia, dynapenia and those components.
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prevalence rate of dynapenia was also approximately twofold
higher than that of sarcopenia. However, the average age
of patients with type 2 diabetes in the present study
(73.9 – 6.6 years) was approximately 10 years younger than the
previous reports29. In addition, 38.8 and 62.4% of patients with
type 2 diabetes aged ≥65 years showed low handgrip and knee
extension strength in the present study, respectively, and this
prevalence was higher than that of the Japanese general elderly
population30. It is possible that type 2 diabetes might complicate
muscle weakness at a younger age than the general population.
Therefore, the typical characteristics of muscle dysfunction in
elderly patients with type 2 diabetes could be lower muscle
strength in the extremities, but not a decrease in muscle volume
compared with individuals without type 2 diabetes. Furthermore,
impaired knee extension strength was observed frequently, even
at the age of <65 years (Figure 1), suggesting that the muscle
strength of lower limbs could be a better indicator of muscle dys-
function than the grip strength in patients with type 2 diabetes.
Sarcopenia is known to be a risk factor for incidental falls in
general elderly people31. In the present study, the complication
of dynapenia increased the incidence of falls, as well as sarcope-
nia (47.8% vs 58.3%) in patients with type 2 diabetes. There-
fore, we should be aware of dynapenia, as well as sarcopenia,
to prevent incidental falls and fractures among elderly patients
with type 2 diabetes.
Sarcopenia and dynapenia were observed in elderly patients
with longer duration of diabetes, and the difference of clinical
characteristics between these comorbidities was adiposity, such
as BMI, %body fat and visceral fat area. Sarcopenic patients
showed low BMI, whereas dynapenic patients showed compara-
ble BMI with patients without sarcopenia and dynapenia. A
previous study reported that obese patients with type 2 diabetes
had lower muscle strength than healthy normal bodyweight
participants5,6. The accumulation of intramuscular fat is inver-
sely associated with lower limb muscle function in elderly indi-
viduals32. In contrast, increased bodyweight could be an
overload to maintain muscle volume. Indeed, high %body fat
was signiﬁcantly and independently associated with the risk of
dynapenia in patients with type 2 diabetes in the present study.
Elderly obese patients with type 2 diabetes, therefore, might
have a higher prevalence of dynapenia, but not sarcopenia.
However, because the intramuscular fat, body fat mass by site
and adipokine levels were not evaluated, the detailed mecha-
nism for developing dynapenia could not be clariﬁed in the
present study.
AGEs, which are produced through non-enzymatic glycation,
are accumulated in various tissues under the diabetic condition;
that is, chronic hyperglycemia9–12. Skin AF, representing the
accumulation of AGEs, was inversely associated with SMI, grip
strength and knee extension strength in an adjusted multivari-
ate logistic regression model in the present study. As reported
previously, reduced muscle mass, regarded as the primary phe-
notype of sarcopenia, is associated with accumulated AGEs in
humans as they age33. Oxidative stress and inﬂammatory
Table 1 | Clinical characteristics of the study patients with sarcopenia and dynapenia
Control
(n = 131)
Sarcopenia
(n = 12)
P-value (control
vs sarcopenia)
Dynapenia
(n = 23)
P-value (control
vs dynapenia)
P-value (sarcopenia
vs dynapenia)
Age (years) 60.7 – 11.8 70.8 – 12.6 0.006 73.0 – 7.6 <0.001 0.523
Female (%) 37.4 33.3 1.000 60.9 0.041 0.164
Incident of fall (%) 16.0 58.3 0.002 47.8 0.001 0.725
BMI (kg/m2) 26.6 – 4.7 20.3 – 2.5 <0.001 27.3 – 5.2 0.550 <0.001
%Body fat (%) 30.2 – 8.0 22.5 – 8.0 0.002 34.6 – 8.6 0.016 <0.001
Visceral fat area (cm2) 109 – 50 52 – 38 0.002 121 – 56 0.371 0.004
Duration of diabetes (years) 11.0 – 7.6 18.3 – 11.9 0.003 17.0 – 10.1 0.012 0.657
HbA1c (%) 7.1 – 1.1 7.1 – 0.9 0.812 7.2 – 0.8 0.943 0.711
Skin AF (AU) 2.57 – 0.52 3.34 – 0.70 <0.001 2.91 – 0.54 0.005 0.049
Pentosidine (lg/mL) 0.0653 – 0.0312 0.1025 – 0.0609 <0.001 0.0766 – 0.0499 0.257 0.326
TG (mg/dL) 168 – 184 127 – 47 0.462 182 – 17 0.562 0.327
HDL (mg/dL) 55 – 16 62 – 28 0.394 51 – 13 0.314 0.103
Dyslipidemia (%) 50.4 16.7 0.033 47.8 1.000 0.139
SBP (mmHg) 139 – 20 137 – 13 0.687 129 – 30 0.051 0.389
DBP (mmHg) 84 – 15 74 – 5 <0.001 77 – 8 0.001 0.348
Hypertension (%) 55.7 41.7 0.38 56.5 1.000 0.489
Diabetic neuropathy (%) 55.0 58.3 1.000 52.2 0.824 1.000
eGFR (mL/min/1.73 m3) 73.7 – 23.4 58.4 – 19.2 0.030 53.3 – 20.5 <0.001 0.446
EC (kcal/day) 123 – 186 24 – 43 <0.001 73 – 88 0.048 0.104
Data are shown as the mean value – standard deviation. %Body fat, percentage of body fat; AF, autofluorescence; BMI, body mass index; DBP, dias-
tolic blood pressure; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated glomerular filtration rate; HbA1c, glycated
hemoglobin; HDL, high density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.
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Table 2 | Odds ratios of lower muscle mass, strength and physical function in patients with type 2 diabetes
SMI < cut-off value Grip strength < cut-off value
Univariate Multivariate Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age 1.05 1.01–1.10 0.028 NS 1.11 1.06–1.16 <0.001 1.09 1.04–1.15 <0.001
Female NS NS NS NS
%Body fat 0.85 0.78–0.91 <0.001 0.85 0.77–0.92 <0.001 NS NS
HbA1c NS NS NS NS
Skin AF 7.4 2.82–19.45 <0.001 6.38 1.93–21.08 0.002 4.65 2.22–9.73 <0.001 3.55 1.57–8.00 0.02
Pentosidine 1.02 1.01–1.03 <0.001 1.02 1.00–1.03 0.013 1.01 1.00–1.02 0.009 NS
eGFR NS NS 0.96 0.94–0.98 <0.001 0.97 0.95–0.99 0.023
Diabetic
neuropathy
NS NS NS NS
EC NS NS NS NS
Gait speed < cutoff value Knee extension strength < cutoff value
Univariate Multivariate Univariate Multivariate
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 1.15 1.05–1.25 0.002 1.16 1.06–1.27 0.002 NS NS
Female NS NS 2.78 1.42–5.42 0.003 NS
%Body fat NS NS 1.08 1.04–1.13 <0.001 1.10 1.05–1.15 <0.001
HbA1c NS NS NS NS
Skin AF NS NS 2.68 1.46–4.95 0.002 3.68 1.87–7.23 <0.001
Pentosidine NS NS 1.01 1.00–1.02 0.039 NS
eGFR 0.96 0.93–0.99 0.012 NS NS NS
Diabetic
Neuropathy
NS NS 2.09 1.11–3.92 0.022 NS
EC NS NS NS NS
%Body fat, percentage of body fat; AF, autofluorescence; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated
glomerular filtration rate; HbA1c, glycated hemoglobin; NS, not significant.
Table 3 | Odds ratios of sarcopenia and dynapenia complications in type 2 diabetes patients
Sarcopenia Dynapenia
Univariate Multivariate Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Age 1.09 1.02–1.17 0.01 NS 1.13 1.07–1.21 <0.001 1.14 1.07–1.21 <0.001
Female NS NS 2.6 1.05–6.46 0.039 NS
%Body fat 0.89 0.82–0.96 0.003 0.91 0.83–0.99 0.045 1.07 1.01–1.14 0.018 1.11 1.03–1.19 0.004
HbA1c NS NS NS NS
Skin AF 10.08 3.08–32.95 <0.001 7.73 2.13–28.02 0.002 3.41 1.42–8.21 0.006 3.03 1.07–8.54 0.036
Pentosidine 1.02 1.01–1.04 0.002 1.02 1.00–1.03 0.017 NS NS
eGFR 0.97 0.94–0.99 0.031 NS NS NS
Diabetic
Neuropathy
NS NS NS NS
EC NS NS NS NS
%Body fat, percentage of body fat; AF, autofluorescence; EC, energy consumption of three or more metabolic equivalents; eGFR, estimated
glomerular filtration rate; HbA1c, glycated hemoglobin; NS, not significant.
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cytokines are increased by AGEs34. In addition, AGEs induce
cross-link and breakdown of muscular protein in elderly
humans and a rodent aging model35. The expression of AGEs
receptors in muscle tissue is increased with aging36,37, suggest-
ing that the intracellular signaling of AGEs–AGEs receptors is
accelerated in the muscle of elderly patients with diabetes.
AGEs levels in the circulation and in the various tissues are
increased under the diabetic condition9–12. AGEs accumulation
in the hind limb muscles of diabetic mice is associated with the
decline in muscle mass, muscle endurance and regenerative
capacity38. Furthermore, it was reported in a human study that
AGEs accumulation in the fast twitch muscle ﬁbers cross-links
with muscle collagen, increases muscle stiffness and reduces the
tonic force of the muscle contraction14,39,40. Thus, it is sug-
gested that accumulated AGEs levels are associated with muscle
mass reduction and sarcopenia in patients with type 2 diabetes.
HbA1c was not associated with low muscle mass, grip
strength and knee extension strength in the present study. We
recently showed that lower limb muscle strength was inversely
associated with skin AF, but not associated with HbA1c in
patients with type 1 diabetes14. It was also reported recently
that skin AF reﬂects integration over the past 15 years’ long-
term glycemic control, but not present glycemic control in
patients with type 1 diabetes41. These results suggest that mus-
cle weakness reﬂects long-term glycemic control in both
patients with type 1 and type 2 diabetes. The serum pento-
sidine was not inversely associated with muscle strength on an
adjusted multivariate logistic regression model (including
covariate of skin AF) in the present study. The duration of
type 2 diabetes was positively correlated with skin AF and
serum pentosidine, but not HbA1c signiﬁcantly (Appendix S4).
Also, serum pentosidine was positively correlated with skin AF.
Serum pentosidine was inversely associated with eGFR. Taken
together, it is suggested that chronic hyperglycemia, aging and
a long duration of disease increase the accumulation of AGEs,
which could contribute to impaired muscle strength in patients
with type 2 diabetes according to the present study. Improve-
ments of glycemic control could attenuate the accumulation of
AGEs. Skin AF was inversely associated with EC. Physical inac-
tivity is a related factor for obesity and type 2 diabetes, both of
which can accelerate the formation and accumulation of AGEs.
In the present study, patients with type 2 diabetes were associ-
ated with a high prevalence of sarcopenia and dynapenia, even
for those aged <65 years. Therefore, the early diagnosis of mus-
cle weakness is important, and good glycemic control and
weight management with exercise and dietary intervention
might be beneﬁcial to prevent the progression of muscle weak-
ness in these patients.
Several studies have showed that the use of statins is associ-
ated with muscle weakness42, but such a ﬁnding was not con-
sistent in the other studies, including the present study. In
addition, the participants in the present study had type 2 dia-
betes, which could be a strong inducer of muscle weakness.
Therefore, we could not ﬁnd any relationship between the use
of statins and the prevalence of sarcopenia or dynapenia in the
present study.
The present study had several limitations. First, it is impossi-
ble to infer causality because of the cross-sectional design,
although we showed a signiﬁcant association between AGEs
accumulation and sarcopenia and dynapenia in patients with
type 2 diabetes. Second, there was no information about what
the participants ate, which could affect both muscle mass and
strength. Insufﬁcient protein intake might result in the progres-
sion of sarcopenia or decline in muscle mass1,2. Third, we could
not evaluate biomarkers of inﬂammation (such as tumor necro-
sis factor-a, interleukin-6), growth factors (such as insulin-like
growth factor) or adipokines (such as leptin, adiponectin)43.
Finally, the small sample size of participants from a single hos-
pital in Japan was a major limitation to generalizing this result.
Therefore, further study is necessary to clarify the prevalence
rate of dynapenia, and the relationship between AGEs and
muscle weakness in a multi-institutional cohort study.
In conclusion, the prevalence rate of dynapenia was higher
than sarcopenia. Dynapenia tended to be observed in obese
patients with type 2 diabetes. Finally, accumulated AGEs was
an independent factor for sarcopenia and dynapenia in patients
with type 2 diabetes.
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